GxP Data Integrity: ALCOA+ and Data Governance in Regulated Environments
Gap assessment, remediation, and governance for GxP Data Integrity per ALCOA+, MHRA, WHO TRS 1010, and FDA 2018. In a regulated industry, Data Integrity is not a peripheral technical concern — it is a business continuity imperative.
Why Data Integrity is an absolute regulatory priority
- FDA, EMA, MHRA, and WHO have each published dedicated Data Integrity guidance in the past decade, reflecting a systemic crisis affecting pharmaceutical companies of all sizes
- Consequences of Data Integrity failures include Critical GMP inspection observations, FDA Warning Letters, Import Alerts, and manufacturing authorization revocations
- ALCOA+ principles are required by all major international guidance: MHRA 2018, WHO TRS 1010, FDA 2018, EudraLex Annex 11
- Hybrid systems (paper + electronic) and standalone systems account for the highest concentration of inspection observations
- Technical remediation resolves immediate gaps, but only a structured Data Governance program ensures long-term sustainability
Our approach
Dalia IA Engineering Studio provides specialized gap assessment, remediation, and governance services for GxP Data Integrity, built on rigorous application of principal international guidance and 20+ years of hands-on GxP experience. We support organizations not only in immediate technical remediation, but in building a governance system that makes Data Integrity a structural organizational attribute.
Discovery, System Inventory, and Data Flow Mapping
- GxP system inventory and data flow collection
- Review of existing SOPs and interviews with key personnel (QA, production, laboratory, IT)
- Data flow mapping: visual tracing of every GxP-relevant data element across the organization's systems
- Identification of critical vulnerability points: manual transcription steps, non-validated interfaces, standalone systems, unprotected data formats
Technical and Regulatory Assessment Against ALCOA+ and International Guidance
- Structured evaluation of each system against ALCOA+, MHRA 2018, WHO TRS 1010, and FDA 2018 requirements
- Analysis of electronic (audit trail, access, backup), hybrid (paper/electronic interface), and standalone systems
- Raw data management verification: original retention, accessibility, modification protection
- Gap severity classification: Critical / Major / Minor with regulatory mapping for each gap
Remediation Plan and Data Governance Program
- Gap Report with concrete actions, owners, timelines, and effectiveness verification criteria
- Data Governance Program: updated policies and SOPs, continuous training program, Data Integrity KPIs
- Risk-based audit trail review program
- Periodic self-inspection with ALCOA+ checklists
- Organizational data integrity culture: OOS/OOT management, anomaly reporting, no-blame culture
Deliverables and outputs
- GxP system inventory and data flow map
- Gap Assessment Report (Critical / Major / Minor)
- Remediation Plan with owners and timelines
- Data Governance Program framework
- Updated policies and SOPs (ALCOA+)
- Audit trail review procedures
- ALCOA+ self-inspection checklist template
- Data Integrity KPIs for periodic monitoring
- Documentation for FDA, EMA, MHRA, AIFA inspections
Regulatory references
Numbers that matter
Studio active since 2004
Pharma, biotech, medical devices
Multinationals and SMEs
No open major findings
Who this is for
- Data Integrity Officer
- QA Manager
- Validation Manager
- Analytical Laboratory Manager
- IT Manager in GxP environments
- Regulatory Affairs Manager
Operational benefits
Unique multidisciplinary expertise
Data Integrity requires rare combined competencies: deep regulatory knowledge (MHRA, WHO, FDA, EudraLex), technical capability to analyze electronic and hybrid systems, and understanding of GxP production and laboratory processes. Our team integrates all three.
Complete data flow mapping
Our capability to visually trace every GxP-relevant data element across multi-system environments — including hybrid and standalone systems — provides the foundation for an effective, non-superficial remediation strategy.
Sustainable governance over time
Technical remediation resolves immediate gaps, but long-term Data Integrity sustainability requires a structured governance program. Dalia IA builds systems that make Data Integrity a structural organizational attribute, not a reactive response to inspections.
Inspection-ready documentation
All deliverables are structured to withstand FDA, EMA, MHRA, AIFA inspections — with critical evidence and regulatory traceability for every identified gap and every remediation action.
The ALCOA+ Principles: Foundation of GxP Data Integrity
ALCOA — originally codified by the FDA — defines five fundamental attributes that every GxP data record must possess:
- Attributable: data must be unambiguously traceable to the person or system that generated or modified it.
- Legible: data must be readable, permanent, and unalterable.
- Contemporaneous: data must be recorded at the time the activity occurs, not retrospectively.
- Original: the original record — the raw data — must be preserved and accessible.
- Accurate: data must faithfully reflect the observed or measured reality.
The “+” of ALCOA+ adds four complementary attributes: Complete, Consistent, Enduring, Available.
The Regulatory Framework
MHRA Data Integrity Definitions and Guidance for Industry (2018) — the most operationally detailed international Data Integrity guidance, widely recognized as international best practice.
WHO Technical Report 1010, Annex 4 (2022) — updated WHO framework for pharmaceutical data integrity governance.
FDA Guidance for Industry: Data Integrity and Compliance With Drug CGMP (2018) — the FDA’s Q&A format guidance addressing complete data definition, chromatographic raw data, standalone systems, backup, and error management.
EudraLex Annex 11 — contains directly relevant requirements: automated audit trails, data protection, access control, and periodic data integrity verification.
ISPE GAMP 5 Good Practice Guide: Data Integrity — Key Concepts (2022) — practical framework for implementing Data Integrity principles in GxP computerized systems.
Audit Trail Review
Configuring a compliant audit trail is necessary but not sufficient — regular review by qualified personnel is itself a GxP requirement. An adequate audit trail review covers: data modifications in production and analytical systems, unauthorized or failed login attempts, system configuration changes, instrument parameter modifications, off-hours operations, and sequence anomalies.
Data Flow Mapping
Data flow mapping traces the path of every GxP-relevant data element across the organization’s systems — from origin through intermediate processing and analysis to final archiving. It identifies critical Data Integrity vulnerability points: manual transcription steps, non-validated system interfaces, unconnected standalone systems, data stored in unprotected formats.
Raw Data Management
Raw data — original, unprocessed data — is the central object of Data Integrity requirements. MHRA and FDA guidance are explicit: raw data must be retained in its original form, accessible, readable, and protected from modification.
Our Service: Gap Assessment, Remediation, and Data Governance
Gap Assessment: three-phase structured evaluation covering discovery (system/data flow inventory, existing SOPs, key personnel interviews), technical and regulatory assessment against ALCOA+/MHRA/WHO/FDA requirements, and production of a Gap Report with a concrete, actionable Remediation Plan.
Data Governance Program: beyond immediate remediation, sustainable Data Integrity requires a governance architecture: updated policies and SOPs, continuous training, Data Integrity KPIs, risk-based audit trail review program, periodic self-inspection, and an organizational culture of data integrity.
Why Dalia IA
- 20+ years of GxP pharmaceutical and life sciences experience
- Deep expertise in MHRA, WHO TRS 1010, FDA 2018, Annex 11
- Experience with electronic, paper, and hybrid systems
- Complete data flow mapping capability across multi-system environments
- Track record building sustainable Data Governance programs
- Inspection-ready deliverables for FDA, EMA, MHRA, AIFA
Frequently Asked Questions
What is GxP Data Integrity in the pharmaceutical industry?
GxP Data Integrity is the assurance that scientific, manufacturing, and clinical data is complete, accurate, consistent, and unaltered throughout its lifecycle. The foundational principles are captured in the ALCOA+ acronym (Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available), required by MHRA, WHO TRS 1010, FDA 2018, and EudraLex Annex 11.
What are the key international Data Integrity guidance documents?
The principal guidance documents are: MHRA Data Integrity Guidance (2018, UK), WHO Technical Report 1010 Annex 4 (2022), FDA Guidance 'Data Integrity and Compliance With Drug CGMP' (2018, USA), and EudraLex Annex 11 (EU). ISPE has also published a dedicated Good Practice Guide within the GAMP 5 framework.
What is raw data and why does it matter for Data Integrity?
Raw data is the original, unprocessed data in the form generated by the instrument or system, before any processing or calculation. It must be retained in its original form, accessible and unalterable. It is the primary evidence of GxP activity: missing or altered raw data is a serious Data Integrity violation and one of the most frequently cited findings in FDA and EMA inspections.
What does a Data Integrity gap assessment typically cover?
A comprehensive Data Integrity gap assessment covers: electronic system configurations (audit trail, access control, backup), hybrid system interfaces (paper-to-electronic), standalone systems, raw data management and archiving, audit trail review procedures, personnel training, and organizational practices for OOS/OOT management and anomaly reporting. Findings are classified by severity: Critical, Major, or Minor.
What is the difference between a Data Integrity remediation plan and a Data Governance program?
A remediation plan addresses specific, identified gaps: concrete corrective actions with owners, timelines, and completion criteria. A Data Governance program is a broader, ongoing framework that sustains Data Integrity over time: updated SOPs, training programs, periodic KPI monitoring, self-inspection programs, and an organizational culture of data integrity. Both are necessary — remediation fixes today's gaps; governance prevents tomorrow's.
Ready to strengthen your organization's Data Integrity?
Request a free preliminary Data Integrity Gap Assessment. We evaluate your ALCOA+ status and define the action plan.